https://www.selleckchem.com/pr....oducts/Abiraterone.h
4, 95% CI 1.1-26.0, = 0.035). Stroke mortality at 30 days was nonsignificantly higher in SLE than non-SLE patients, but all-cause mortality (37.5% compared to 8.3%, 0.001), recurrence of stroke (30% compared to 9.2%, = 0.002), and poststroke seizure (22.5% compared to 3.3%, = 0.001) were significantly more common in SLE patients after an observation of 8.4 ± 6.1 years. SLE was independently associated with all-cause mortality and stroke recurrence over time. Stroke in patients with SLE is associated with a poorer outcome than m
Like
Comment
Share
